07.28.14
Royal Philips has agreed to acquire Unisensor, a supplier of bacteria and cell analysis equipment. Terms of the deal were not disclosed.
The Unisensor technology is expected to strengthen Philips’ capabilities in the field of patient sample analysis such as blood testing for applications in oncology therapy monitoring. These innovations aim to enhance patient triage and treatment at the point-of-care (i.e. near the patient), thereby helping to improve patient care at a lower cost.
Upon closing of the transaction, expected in the third quarter of 2014 and subject to certain closing conditions, Unisensor, headquartered in Allerød, Denmark, will become part of Philips’ Healthcare Incubator within Philips Innovation, Group & Services.
“Philips’ Healthcare Incubator has already produced promising early-stage businesses in the area of near-patient testing and monitoring for the hospital and the home,” said Perry van Rijsingen, General Manager for Philips Healthcare Incubator. “The acquisition of Unisensor will expand our technology platforms for miniaturized, mobile diagnostic solutions and support our ambition to become a leader in this new growth market for Philips.”
Unisensor was founded in 1997 and is a privately held company with approximately 35 employees. Unisensor’s current product line includes oCelloScope, an analytical instrument that is, amongst other applications, used within cancer cell studies on a research application basis. The company has partnerships with leading companies in animal health and water analysis, which Philips intends to continue.
The acquisition follows a disappointing quarter for Philips --- Healthcare net sales fell 4 percent compared with Q2 2013 and the segment's EBITA margin, excluding restructuring and acquisition-related charges, declined to 10.5 percent, a decrease of 3.8 percentage points year-on-year. Equipment orders were up, posting a high single-digit increase, while North America experienced a double-digit decline.
The Unisensor technology is expected to strengthen Philips’ capabilities in the field of patient sample analysis such as blood testing for applications in oncology therapy monitoring. These innovations aim to enhance patient triage and treatment at the point-of-care (i.e. near the patient), thereby helping to improve patient care at a lower cost.
Upon closing of the transaction, expected in the third quarter of 2014 and subject to certain closing conditions, Unisensor, headquartered in Allerød, Denmark, will become part of Philips’ Healthcare Incubator within Philips Innovation, Group & Services.
“Philips’ Healthcare Incubator has already produced promising early-stage businesses in the area of near-patient testing and monitoring for the hospital and the home,” said Perry van Rijsingen, General Manager for Philips Healthcare Incubator. “The acquisition of Unisensor will expand our technology platforms for miniaturized, mobile diagnostic solutions and support our ambition to become a leader in this new growth market for Philips.”
Unisensor was founded in 1997 and is a privately held company with approximately 35 employees. Unisensor’s current product line includes oCelloScope, an analytical instrument that is, amongst other applications, used within cancer cell studies on a research application basis. The company has partnerships with leading companies in animal health and water analysis, which Philips intends to continue.
The acquisition follows a disappointing quarter for Philips --- Healthcare net sales fell 4 percent compared with Q2 2013 and the segment's EBITA margin, excluding restructuring and acquisition-related charges, declined to 10.5 percent, a decrease of 3.8 percentage points year-on-year. Equipment orders were up, posting a high single-digit increase, while North America experienced a double-digit decline.